The pandemic within:
tackling brain vulnerability in COVID19 at high resolution (NEUROCOV)
The European research project NeuroCOV aims to investigate neurological and neuropsychological complications due to COVID-19. The impact of this phenomenon, called NeuroCOVID, is immense, and society and healthcare systems are at risk of unprecedented consequences.
Being a multidisciplinary and international consortium of 10 institutions, NeuroCOV strives to enhance the medical predicaments of developing NeuroCOVID, advance monitoring and treatment, and address the societal consequences of this major global problem.
In particular, our Team manages biosampling, clinical/neurological assessments and collection clinical data of the Italian cohort by taking advantage of the long lasting and fruitful collaboration with IRCCS Istituto Clinico Humanitas and “Luigi Sacco” University Hospital
TEAM
Francesca Calcaterra PhD - Senior staff scientist
Clara Di Vito PhD - Senior staff scientist
Anna Carletti – Lab manager
Alessandro Frigo - Post-doctoral fellow
Annalisa Imperiali - PhD student, bioinformatitian
COLLABORATIONS
Department of Biomedical and Clinical Sciences
University of Milan, Milan, Italy
Neuromuscular and Neuroimmunology Unit
IRCCS Humanitas Research Hospital, Rozzano, Italy
Neurology Unit
“Luigi Sacco” University Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
Department of Infectious Diseases
“Luigi Sacco” University Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
DZNE - German Center for Neurodegenerative Diseases
Göttingen, Germany
Human Technopole
Milan, Italy
FUNDing
European Health and Digital Executive Agency
Project ID: HORIZON-HLTH-2021-DISEASE-04
The pandemic within: tackling brain vulnerability in COVID-19 at high resolution: NEUROCOV
Domenico Mavilio
Head of Unit (UNIMIL) and Head of WP1
HMGU - Helmholtz Association of German Research Centres
Germany
Katholieke Universiteit Leuven
Leuven, Belgium
Institute for Molecular Medicine
Helsinki, Finlan
Umeå University
Umeå, Sweden
VU University Medical Center
Amsterdam, Netherlands
Ben-Gurion University of the Negev
Be'er Sheva, Israel
related publications
Antibody response to three-dose anti-SARS-CoV-2 mRNA-vaccination in treated solid cancer patients
Dalu D, Tarkowski M, Ruggieri L, Cona MS, Gabrieli A, De Francesco D, Fasola C, Ferrario S, Gambaro A, Masedu E, Parma G, Rulli E, De Stradis C, Mavilio D, Calcaterra F, Manoni F, Riva A, La Verde N.
Int J Cancer. 2023 Dec 15. doi: 10.1002/ijc.34817.